Double indirect hernia: an indirect inguinal hernia with two hernia sacs, without a concomitant direct hernia component (as seen in a pantaloon hernia). Hiatus hernia: a hernia due to "short oesophagus" — insufficient elongation — stomach is displaced into the thorax
Littres hernia: a hernia involving a Meckels diverticulum. It is named after the French anatomist Alexis Littré (1658–1726). Lumbar hernia: a hernia in the lumbar region (not to be confused with a lumbar disc hernia), contains the following entities:
Petits hernia: a hernia through Petits triangle (inferior lumbar triangle). It is named after French surgeon  Jean Louis Petit (1674–1750). Grynfeltts hernia: a hernia through Grynfeltt-Lesshaft triangle (superior lumbar triangle). It is named after physician Joseph Grynfeltt (1840–1913). Maydls hernia: two adjacent loops of small intestine are within a hernial sac with a tight neck. The intervening portion of bowel within the abdomen is deprived of its blood supply and eventually becomes necrotic. Obturator hernia: hernia through obturator canal
Parastomal hernias, which is when tissue protrudes adjacent to a stoma tract. Paraumbilical hernia: a type of umbilical hernia occurring in adults
Perineal hernia: a perineal hernia protrudes through the muscles and fascia of the perineal floor. It may be primary but usually is acquired following perineal prostatectomy, abdominoperineal resection of the rectum, or pelvic exenteration. Properitoneal hernia: rare hernia located directly above the peritoneum, for example, when part of inguinal hernia projects from the deep inguinal ring to the preperitoneal space.
Mobocertinib, sold under the brand name Exkivity, is used for the treatment of non-small cell lung cancer.The most common side effects include diarrhea, rash, nausea, stomatitis, vomiting, decreased appetite, paronychia, fatigue, dry skin, and musculoskeletal pain.Mobocertinib is a small molecule tyrosine kinase inhibitor. Its molecular target is epidermal growth factor receptor (EGFR) bearing mutations in the exon 20 region. Mobocertinib is an irreversible kinase inhibitor, forming a covalent bond with the cysteine 797 in the EGFR active site, leading to sustained inhibition of EGFR enzymatic activity. The irreversible binding leads to increased potency via higher affinity binding, more sustained EGFR kinase activity inhibition, and greater overall selectivity, as only a limited number of other kinases possess a cysteine in the equivalent position.Mobocertinib was approved for medical use in the United States in September 2021. It is a first-in-class oral treatment to target EGFR Exon20 insertion mutations. Medical uses
Mobocertinib is indicated for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. Mechanism of action
Mobocertinib acts to inhibit EGFR exon 20 insertion mutations at a lower concentration than it does on wild-type proteins. Pharmacokinetics
The volume of distribution of Mobocertinib at steady state is 3,509 L.  The mean oral bioavailability of Mobocertinib is 37%. The median Tmax is 4 hours. The average half-life of Mobocertinib and its metabolites is 18 hours. Mobocertinib is metabolized by CYP3A enzymes.